PARLIAMENTARY WRITTEN QUESTION
(7 April 2025)

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure that all NICE-approved medicines for osteoporosis are included in (a) ICS and (b) local formularies.

Asked by:
Matt Bishop (Labour)

The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS based on an assessment of their costs and benefits.

The NHS in England is legally required to fund medicines recommended by the NICE, usually within three months of final guidance.

The 2025/26 NHS Standard Contract, which applies to all contracts between NHS commissioners and providers, stipulates that, where any service involves or may involve the prescribing of medicines, the provider must ensure that its formulary reflects all relevant positive NICE technology appraisals.

The NICE has also published guidance on developing and updating local formularies, which is intended to support commissioners and healthcare providers, including those working within integrated care systems, in developing formularies that reflect local needs, reducing variation in prescribing, and allowing for the rapid adoption of new medicines and treatments. This guidance is available at the following link:

https://www.nice.org.uk/guidance/mpg1

Answered by:
()